Skip to main content
SpringerLink
Log in

Prenatal Antidepressant Exposure and Childhood Autism Spectrum Disorders: Cause for Concern?

  • Leading Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

There is empirical evidence for a role for serotonin in autism . In experimental animals, early life exposure to serotonergic antidepressants or maternal stress affects brain development, with subsequent changes in serotonin tone in adult animals. Recently, antidepressant exposure during pregnancy has been associated with autism in epidemiological studies. At least part of the association is potentially explained by maternal depression or factors associated with depression. Importantly, even if there is no causal relation between prenatal antidepressant exposure and autism, use of antidepressants during pregnancy is a marker of potential problems later in life across five independent study populations, and exposed children may need special attention regardless of the underlying mechanism. Future studies need to disentangle the effects of maternal depression and antidepressant use during pregnancy while adjusting for the postnatal environment. One promising strategy is to use results from basic science to guide the inclusion of potential biological intermediates in advanced epidemiological studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrade S, Raebel M, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1–e5.

  2. Bjorn AM, Norgaard M, Hundborg HH, Nohr EA, Ehrenstein V. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. Clin Epidemiol. 2011;3:149–56.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Prevalence of antidepressant use during pregnancy in Denmark, a Nation-Wide Cohort Study. PLoS One. 2013;8(4):e63034.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Knight M Kenyon S, Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk JJ, editors. On behalf of MBRRACE—UK. Saving lives, improving mothers’ care—lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009–12. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2014.

  5. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–92.

    Article  CAS  PubMed  Google Scholar 

  6. Grzeskowiak LE, Gilbert AL, Morrison JL. Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues. Drug Saf. 2011;34(11):1027–48.

    Article  CAS  PubMed  Google Scholar 

  7. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118(1):111–20.

    Article  PubMed  Google Scholar 

  9. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–83.

    Article  CAS  PubMed  Google Scholar 

  10. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3):e600–8.

    Article  PubMed  Google Scholar 

  11. Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J. Prenatal antidepressant exposure and behavioral problems in early childhood—a cohort study. Acta Psychiatr Scand. 2013;127(2):126–35.

    Article  CAS  PubMed  Google Scholar 

  12. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336(4):258–62.

    Article  CAS  PubMed  Google Scholar 

  13. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology. 2011;217(2):211–9.

    Article  CAS  PubMed  Google Scholar 

  14. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry. 2006;163(6):1026–32.

    Article  PubMed  Google Scholar 

  15. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med. 2007;161(1):22–9.

    Article  PubMed  Google Scholar 

  16. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12.

    Article  PubMed  Google Scholar 

  17. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5:449–59.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406–15.

    Article  CAS  PubMed  Google Scholar 

  20. El Marroun H, White TJ, van der Knaap NJ, Homberg JR, Fernandez G, Schoemaker NK, et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br J Psychiatry. 2014;205(2):95–102.

    Article  PubMed  Google Scholar 

  21. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241–8.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Petersen I, Evans S, Nazareth I. Prenatal exposure to selective serotonin reuptake inhibitors and autistic symptoms in young children: another red herring? Br J Psychiatry. 2014;205(2):105–6.

    Article  PubMed  Google Scholar 

  23. Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2014 26.

  24. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65(6):591–8.

    Article  PubMed  Google Scholar 

  25. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68(11):1095–102.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Colvert E, Tick B, McEwen F, Stewart C, Curran SR, Woodhouse E, et al. Heritability of autism spectrum disorder in a UK population-based twin sample. JAMA Psychiatry. 2015;72(5):415–23.

    Article  PubMed  Google Scholar 

  27. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Smith GD. Epidemiology, epigenetics and the ‘Gloomy Prospect’: embracing randomness in population health research and practice. Int J Epidemiol. 2011;40(3):537–62.

    Article  PubMed  Google Scholar 

  29. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3(2):97–106.

  30. Devlin AM, Brain U, Austin J, Oberlander TF. Prenatal Exposure to Maternal Depressed Mood and the MTHFRC677T Variant Affect SLC6A4 Methylation in Infants at Birth. PLoS One. 2010;5(8):e12201.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2009;374(9701):1627–38.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009;86(6):672–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science. 2004;306(5697):879–81.

    Article  CAS  PubMed  Google Scholar 

  34. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31(1):47–57.

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci. 2008;28(1):199–207.

    Article  CAS  PubMed  Google Scholar 

  36. Peters DA. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress influences brain development. Pharmacol Biochem Behav. 1990;35(4):943–7.

    Article  CAS  PubMed  Google Scholar 

  37. Hayashi A, Nagaoka M, Yamada K, Ichitani Y, Miake Y, Okado N. Maternal stress induces synaptic loss and developmental disabilities of offspring. Int J Dev Neurosci. 1998;16(3–4):209–16.

  38. Gidaya NB, Lee BK, Burstyn I, Yudell M, Mortensen EL, Newschaffer CJ. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J Autism Dev Disord. 2014;44(10):2558–67.

    Article  PubMed  Google Scholar 

  39. Grzeskowiak LE, Gilbert AL, Sorensen TI, Olsen J, Sorensen HT, Pedersen LH, et al. Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age. Ann Epidemiol. 2013;23(11):681–7.

    Article  PubMed  Google Scholar 

  40. Bourgeois JA, Coffey SM, Rivera SM, Hessl D, Gane LW, Tassone F, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry. 2009;70(6):852–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. AmJ Epidemiol. 2002;155(2):176–84.

    Article  Google Scholar 

  42. Dulac C, O’Connell LA, Wu Z. Neural control of maternal and paternal behaviors. Science. 2014;345(6198):765–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Vanderweele TJ, Mukherjee B, Chen J. Sensitivity analysis for interactions under unmeasured confounding. Stat Med. 2012;31(22):2552–64.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Tchetgen Tchetgen EJ. Vanderweele TJ. Identification of natural direct effects when a confounder of the mediator is directly affected by exposure. Epidemiology. 2014;25(2):282–91.

    Article  PubMed  Google Scholar 

  45. Levitt P. Serotonin and the autisms: a red flag or a red herring? Arch Gen Psychiatry. 2011;68(11):1093–4.

    Article  PubMed  Google Scholar 

  46. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010;304(8):859–66.

    Article  CAS  PubMed  Google Scholar 

  47. Mill J, Heijmans BT. From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet. 2013;14(8):585–94.

    Article  CAS  PubMed  Google Scholar 

  48. Chen Y, Pedersen LH, Chu WW, Olsen J. Drug exposure side effects from mining pregnancy data. ACM SIGKDD Explorations Newsletter. 2007;9(1):22–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The author has no conflicts of interest. No specific funding was used to assist in the preparation of the review.

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, Obstetrics and Gynecology, Aarhus University, Aarhus, Denmark

    Lars Henning Pedersen

Authors
  1. Lars Henning Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Henning Pedersen.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pedersen, L.H. Prenatal Antidepressant Exposure and Childhood Autism Spectrum Disorders: Cause for Concern?. Pediatr Drugs 17, 443–448 (2015). https://doi.org/10.1007/s40272-015-0141-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-015-0141-5

Keywords

Search

Navigation